The 60 mg twice daily dose did not provide any additional benefit over the 30 mg twice daily dose in pediatric subjects 6 to 11 years of age. After administration of a single 60 mg capsule to healthy subjects, the mean maximum plasma concentration (Cmax) was 131 ng/mL. In these studies, there was no additional reduction in total symptom scores with higher doses of fexofenadine hydrochloride up to 240 mg twice daily. The administration of the 60 mg Cheapest Allegra D contents mixed with applesauce did not have a significant effect on the pharmacokinetics of fexofenadine in adults. Following single dose oral administrations of either the 60 and 180 mg tablet to healthy adult male subjects, mean Cmax were 142 and 494 ng/mL, respectively. Fruit juices such as grapefruit, orange and apple may reduce the bioavailability and exposure of fexofenadine Allegra Or Claritin . The administration of 30 mg ALLEGRA Oral Suspension with a high fat meal decreased the AUC and the mean Cmax by approximately 30 and 47%, respectively in healthy adult subjects. In one Allegra Or Claritin multicenter, randomized, double-blind, placebo-controlled clinical Allegra D Information in subjects 12 years of age and older with chronic idiopathic urticaria (n=259), fexofenadine hydrochloride 180 mg once daily significantly reduced the mean number of wheals (MNW), the mean pruritus score (MPS), and the mean total symptom score (MTSS, the sum of the MPS and MNW scores). Each tablet contains 30, 60, Allegra Or Claritin 180 mg fexofenadine hydrochloride (depending on the dosage strength) and the following excipients: croscarmellose sodium, magnesium stearate, microcrystalline cellulose, and pregelatinized Allegra Or Claritin The aqueous tablet Allegra Or Claritin coating is made from hypromellose, iron oxide blends, polyethylene glycol, povidone, silicone dioxide, and titanium dioxide. Symptom reduction was greater with fexofenadine hydrochloride180 mg than with placebo. In 1 of these 2 studies, conducted in 411 pediatric subjects, all 3 doses of fexofenadine hydrochloride significantly reduced total symptom scores (the sum of the individual scores for sneezing, rhinorrhea, itchy nose/palate/throat, itchy/watery/red eyes) compared to placebo, however, a dose-response relationship was not seen. The mechanism of these interactions has been evaluated in in vitro, in situ, and in vivo animal models. Both enantiomers of fexofenadine hydrochloride displayed approximately equipotent antihistaminic effects.